Gestational Diabetes Global Market Report 2025

Gestational diabetes is a type of diabetes that arises during pregnancy when the body fails to produce enough insulin to adequately regulate blood sugar levels. This condition usually emerges in the second or third trimester and can occur in women without a prior history of diabetes. Gestational diabetes poses risks to both the mother and the baby, including high birth weight, premature delivery, and an increased likelihood of developing type 2 diabetes later in life for both. Management typically involves adjustments to diet, regular exercise, blood sugar monitoring, and, if necessary, insulin therapy to support a healthy pregnancy and childbirth.

Gestational diabetes is categorized into several types, including Type A1, Type A2, and other forms. Type A1 refers to gestational diabetes mellitus (GDM) that develops during pregnancy due to insufficient insulin production to meet the increased demands of this period. Treatment strategies often include blood sugar monitoring, medication, and lifestyle interventions, which may be delivered orally, intravenously, or through other methods. These interventions are commonly implemented in hospitals, clinics, home care settings, and diagnostic centers.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The gestational diabetes market research report is one of a series of new reports from The Business Research Company that provides gestational diabetes market statistics, including gestational diabetes industry global market size, regional shares, competitors with gestational diabetes market share, detailed gestational diabetes market segments, market trends, and opportunities, and any further data you may need to thrive in the gestational diabetes industry. This gestational diabetes market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The gestational diabetes market size has grown strongly in recent years. It will grow from $8.37 billion in 2024 to $9.11 billion in 2025 at a compound annual growth rate (CAGR) of 8.9%. The growth in the historic period can be attributed to increase the risk of diabetes, increased as accuracy in measuring blood glucose levels, increased number of the insurance players, increase in the population of diabetic patients, growing diabetes population.

The gestational diabetes market size is expected to see strong growth in the next few years. It will grow to $12.78 billion in 2029 at a compound annual growth rate (CAGR) of 8.8%. The growth in the forecast period can be attributed to increase in rate of obesity, growing acceptance of cloud-based project arrangements and the expanding use of related devices and apps, increasing prevalence of diabetes due to unhealthy lifestyles among people, increase in public health consciousness, rising prevalence rates of diabetes. Major trends in the forecast period include digital diabetes management apps, closed-loop control systems, diabetes management technology, enzymatic technology, innovative medical technologies.

The forecast of 8.8% growth over the next five years reflects a slight reduction of 0.2% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. The imposition of tariffs may disrupt U.S. prenatal care by increasing costs for continuous glucose monitors and insulin pumps imported from Israel and France, potentially compromising fetal health outcomes and increasing Obstetrics and gynaecology(OB/GYN) practice costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The growing prevalence of obesity is expected to drive the expansion of the gestational diabetes market in the future. Obesity refers to individuals with a body mass index (BMI) of 30 or higher, indicating excessive body fat that can lead to significant health risks. The rise in obesity is influenced by factors such as sedentary lifestyles, the increased intake of high-calorie processed foods, genetic predispositions, and limited access to healthy food and exercise options. Gestational diabetes treatment is particularly important for the obese population, as their increased risk of insulin resistance and excessive weight gain during pregnancy can cause complications for both the mother and baby if left untreated. For example, in March 2024, the World Health Organization (WHO), a Switzerland-based intergovernmental agency, reported that approximately 1 in 8 people worldwide were living with obesity in 2022. This includes 2.5 billion adults aged 18 and older classified as overweight, of which 890 million were living with obesity. Among adults, 43% were overweight, and 16% were obese. Additionally, 37 million children under 5 years old were overweight, and more than 390 million children and adolescents aged 5 to 19 years were overweight, including 160 million living with obesity. As a result, the increasing obese population is driving the growth of the gestational diabetes market.

Leading companies in the gestational diabetes market are focusing on the development of advanced products, such as diagnostic kits, to offer quick, accurate, and convenient methods for early detection of the condition. A diagnostic kit for gestational diabetes is a medical tool used to measure blood glucose levels and detect abnormal glucose tolerance in pregnant women, helping in the early identification and management of the condition. For example, in August 2024, DirectSens GmbH, a biotechnology company based in Austria, introduced the XpressGT RUO kit. This diagnostic kit is designed to detect gestational diabetes, endometriosis, insulin resistance, and liver disease. It measures 2-hydroxybutyrate (2-HB) levels in venous blood, a substance naturally produced by the liver during its normal functions. Elevated 2-HB levels are linked to increased reductive stress, which is associated with various endocrine and obesity-related disorders, including insulin resistance. The kit is compatible with any clinical analyzer and provides results in just 8 minutes, offering a fast and efficient diagnostic solution.

In April 2024, Digostics, a diabetes home-testing provider based in the UK, partnered with AgaMatrix Europe to advance gestational diabetes screening. This collaboration grants AgaMatrix exclusive rights to distribute Digostics' home oral glucose tolerance testing (OGTT) service, GTT@home, to the UK National Health Service (NHS). By utilizing its strong connections and customer base within NHS maternity services, along with its extensive expertise in gestational diabetes monitoring, AgaMatrix aims to accelerate the introduction of GTT@home in the UK market. AgaMatrix Europe is a UK-based company specializing in the production of blood glucose monitoring solutions.

Major players in the gestational diabetes market are Sanofi S.A., AstraZeneca plc, Abbott Laboratories, Eli Lilly and Company, Novo Nordisk A/S, Becton, Dickinson and Company, Boehringer Ingelheim GmbH, Dexcom Inc, Biocon Limited, LifeScan Inc, Ascensia Diabetes Care Holdings AG, Trividia Health Inc., Nipro Diagnostics, Inc., Sernova Corp., ZyVersa Therapeutics, Inc., Peptron Inc., Roche Diabetes Care, DiabetOmics Inc, Merck & Co. Inc., Medtronic plc.

North America was the largest region in the gestational diabetes market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in gestational diabetes report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the gestational diabetes market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The gestational diabetes market consists of revenues earned by entities by providing services such as nutritional counseling, medication management, telemedicine services, lifestyle and exercise guidance. The market value includes the value of related goods sold by the service provider or included within the service offering. The gestational diabetes market also includes sales of metformin, glyburide, and insulin. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Gestational Diabetes Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on gestational diabetes market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for gestational diabetes ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The gestational diabetes market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Types: Type A1; Type A2; Other Types
• 2) By Treatment: Monitoring; Drug Treatment; Non-pharmacological treatment
• 3) By Administration: Oral; Intravenous; Other Administrations
• 4) By End User: Hospitals; Clinics; Home Care Settings; Diagnostic Centers
• Subsegments:
• 1) By Type A1: Diet-Controlled Gestational Diabetes; Exercise-Controlled Gestational Diabetes
• 2) By Type A2: Insulin-Controlled Gestational Diabetes; Oral Medication-Controlled Gestational Diabetes
• 3) By Other Types: Pre-Gestational Diabetes; Gestational Diabetes With Complications
• Companies Mentioned: Sanofi S.A.; AstraZeneca plc; Abbott Laboratories; Eli Lilly and Company; Novo Nordisk A/S; Becton, Dickinson and Company; Boehringer Ingelheim GmbH; Dexcom Inc; Biocon Limited; LifeScan Inc; Ascensia Diabetes Care Holdings AG; Trividia Health Inc.; Nipro Diagnostics, Inc.; Sernova Corp.; ZyVersa Therapeutics, Inc.; Peptron Inc.; Roche Diabetes Care; DiabetOmics Inc; Merck & Co. Inc.; Medtronic plc
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.